59781-10-1

Upstream product

• 59781-09-8 5-(benzyloxy)-2-methylpyridine 1-oxide 
• 108-24-7 acetic anhydride 
• 63793-98-6 5-benzyloxy-2-methyl-pyridine 
• 100-39-0 benzyl bromide 
• 1121-78-4 5-Hydroxy-2-methylpyridine 

Downstream Products

• 59781-11-2 (5-(benzyloxy)pyridin-2-yl)methanol 
• 648415-02-5 [1-(5-Benzyloxy-pyridin-2-yl)-meth-(E)-ylidene]-trimethylsilanyl-amine 
• 647840-12-8 (3R,4S)-4-(5-benzyloxy-2-pyridyl)-3-triisopropylsilyloxy-2-azetidinone 
• 647840-13-9 (3R,4S)-4-(5-benzyloxy-2-pyridyl)-1-(tert-butoxycarbonyl)-3-triisopropylsilyloxy-2-azetidinone 
• 647840-15-1 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-9,10-[(1S)-2-propenylidenedioxy]tax-11-en-13-yl (2R,3S)-3-(5-benzyloxy-2-pyridyl)-3-(tert-butoxycarbonylamino)-2-hydroxypropionate 
• 647840-16-2 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-9,10-[(1S)-2-(morpholino)ethylidenedioxy]tax-11-en-13-yl (2R,3S)-3-(5-benzyloxy-2-pyridyl)-3-(tert-butoxycarbonylamino)-2-hydroxypropionate 
• 647840-14-0 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-9,10-[(1S)-2-propenylidenedioxy]tax-11-en-13-yl (2R,3S)-3-(5-benzyloxy-2-pyridyl)-3-(tert-butoxycarbonylamino)-2-triisopropylsilyloxypropionate 
• 1612163-89-9 (E)-2-(2-(5-(benzyloxy)pyridin-2-yl)vinyl)-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine 
• 262277-51-0 (S)-3-{[7-(3-Amino-propoxy)-4-oxo-4H-quinolizine-2-carbonyl]-amino}-2-benzenesulfonylamino-propionic Acid Trifluoroacetic Acid Salt 
• 262278-27-3 7-benzyloxy-4-oxo-4H-quinolizine-2-carboxylic acid methyl ester 
• 262278-34-2 (S)-2-benzenesulfonylamino-3-{[7-(3-tert-butoxycarbonylamino-propoxy)-4-oxo-4H-quinolizine-2-carbonyl]-amino}-propionic acid tert-butyl ester 
• 262278-59-1 (S)-2-Benzenesulfonylamino-3-({4-oxo-7-[3-(pyrimidin-2-ylamino)-propoxy]-4H-quinolizine-2-carbonyl)-amino)-propionic Acid tert-butyl Ester 
• 59781-08-7 5-benzyloxypyridin-2-carbaldehyde 

Relevant academic research and scientific papers

Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure-Activity Relationships and Lead Candidate Evaluation

Gd-based MRI contrast agents (GBCAs) have come under intense regulatory scrutiny due to concerns of Gd retention and delayed toxicity. Three GBCAs comprising acyclic Gd chelates, the class of GBCA most prone to Gd release, are no longer marketed in Europe

TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE

The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a carbamoyl group; R2 represents a lower alkyl group; both of X1 and X2 represent CH, or any one of X1 and X2 represents a nitrogen atom and the other represents CH; a group of represents a group selected from the group consisting of a pyridinyl, a pyrazinyl, a pyrazolyl, a thiadiazolyl, a triazolyl, an isoxazolyl and a thiazolyl group; and k is zero or 1, or relates to pharmaceutically acceptable salts thereof.

QUINOLINE DERIVATIVES

The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

First chiral synthesis of the N-terminal amino acid congener of nikkomycin Z based on lipase-catalyzed enantioselective acetylation of a primary alcohol possessing two stereogenic centers

A stereoselective synthesis of a versatile chiral synthon possessing two stereogenic centers, (2S,3S)-3-[2-(5-benzyloxypyridyl)]-2-methyl-1,3-propane diol 12 (>99% ee), was achieved by using a chemo-enzymatic method. The conversion of (2S,3S)-12 to the ho

New highly active taxoids from 9β-dihydrobaccatin-9,10-acetals. Part 4

It was shown that a new taxane analogue 3, which exhibited both in vitro antitumor activity and in vivo efficacy by both iv and po administration, was prone to be metabolized by human liver microsomes. We identified a major metabolite, M-1, generated by h

Quinolizinones as integrin inhibitors

The present invention is directed towards novel compounds that are effective inhibitors of integrins, particularly αIIbβ3 or αv integrins such as αvβ3 and αvβ5. One embodiment of the present invention comprises a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt, solvate, or metabolic precursor thereof. R1, R2, R3, and R4 are defined herein.

Substituted 2-acylpyridine-α-(N)-hetarlyhydrazones and medicaments containing the same

Substituted 2-acylpyridine-α-(N)-hetarylhydrazones are described, which are suitable as active substances for the treatment of antimicrobial and in particular antimycobacterial diseases, as well as active substances for the treatment of malaria or malignant tumours. The compounds have a marked synergistic activity combined with inhibitors of folate synthase, dihydrofolic acid reductase, DNA-synthesis and RNA-synthesis.